Sarwish Rafiq

4.3k total citations · 3 hit papers
34 papers, 2.8k citations indexed

About

Sarwish Rafiq is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Sarwish Rafiq has authored 34 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 16 papers in Immunology and 12 papers in Molecular Biology. Recurrent topics in Sarwish Rafiq's work include CAR-T cell therapy research (23 papers), Immunotherapy and Immune Responses (8 papers) and Nanowire Synthesis and Applications (8 papers). Sarwish Rafiq is often cited by papers focused on CAR-T cell therapy research (23 papers), Immunotherapy and Immune Responses (8 papers) and Nanowire Synthesis and Applications (8 papers). Sarwish Rafiq collaborates with scholars based in United States and China. Sarwish Rafiq's co-authors include Renier J. Brentjens, Christopher S. Hackett, Terence J. Purdon, Oladapo Yeku, Mei Song, Xiaojing Ma, Liu C, Dylan J. Drakes, Pei Wang and Ronald C. Hendrickson and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Sarwish Rafiq

32 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Engineering strategies to overcome the current roadblocks in CAR T cell therapy

2019 1.0k citations Sarwish Rafiq, Christopher S. Hackett et al. profile →
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

2018 628 citations Sarwish Rafiq, Oladapo Yeku et al. Nature Biotechnology profile →
Driving CAR T-cells forward

2016 470 citations Sarwish Rafiq, Renier J. Brentjens et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sarwish Rafiq United States	15	2.2k	1.1k	916	767	537	34	2.8k
Meng-Fen Wu United States	16	2.4k 1.1×	1.0k 0.9×	815 0.9×	627 0.8×	743 1.4×	18	2.9k
Rebecca C. Larson United States	19	1.9k 0.9×	947 0.8×	1.3k 1.4×	679 0.9×	630 1.2×	38	3.1k
Terence J. Purdon United States	22	2.9k 1.3×	1.1k 1.0×	963 1.1×	1.0k 1.3×	837 1.6×	41	3.1k
Rachel C. Lynn United States	16	2.4k 1.1×	1.4k 1.3×	938 1.0×	698 0.9×	634 1.2×	30	3.2k
Mathilde Poussin United States	24	2.1k 1.0×	1.1k 1.0×	679 0.7×	767 1.0×	595 1.1×	41	2.8k
Brenda Aguilar United States	19	2.1k 0.9×	1.0k 0.9×	728 0.8×	750 1.0×	585 1.1×	40	2.7k
Eric Yvon United States	28	2.6k 1.2×	1.8k 1.6×	900 1.0×	698 0.9×	867 1.6×	49	3.6k
Bizhi Shi China	28	1.7k 0.8×	1.0k 0.9×	914 1.0×	460 0.6×	305 0.6×	53	2.6k
Valentina Hoyos United States	19	2.1k 1.0×	1.0k 0.9×	838 0.9×	667 0.9×	782 1.5×	35	2.6k
Daniel Sommermeyer United States	25	3.4k 1.6×	1.5k 1.3×	1.2k 1.3×	1.1k 1.5×	1.1k 2.0×	39	3.8k

Countries citing papers authored by Sarwish Rafiq

Since Specialization

Citations

This map shows the geographic impact of Sarwish Rafiq's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarwish Rafiq with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarwish Rafiq more than expected).

Fields of papers citing papers by Sarwish Rafiq

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarwish Rafiq. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarwish Rafiq. The network helps show where Sarwish Rafiq may publish in the future.

Co-authorship network of co-authors of Sarwish Rafiq

This figure shows the co-authorship network connecting the top 25 collaborators of Sarwish Rafiq. A scholar is included among the top collaborators of Sarwish Rafiq based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarwish Rafiq. Sarwish Rafiq is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liu, William, Subir Goyal, Tongrui Liu, et al.. (2024). Antagonizing vasoactive intestinal peptide (VIP) receptors with Muc16CD-directed armored CAR T cells for pancreatic cancer.. Journal of Clinical Oncology. 42(16_suppl). 2558–2558. 1 indexed citations

Liu, Tongrui, et al.. (2024). Muc16CD is a novel CAR T cell target antigen for the treatment of pancreatic cancer. PubMed. 32(4). 200868–200868. 1 indexed citations

Maaskant, Janneke J., Karmella A. Haynes, Heather Lin, et al.. (2024). Obesity Attenuates CAR T-Cell Function in Pediatric B-Cell Acute Lymphoblastic Leukemia. Blood. 144(Supplement 1). 4807–4807.

Rabe, Jennifer L., Chengjing Zhou, Deborah DeRyckere, et al.. (2023). Siglec-15 Promotes Evasion of Adaptive Immunity in B-cell Acute Lymphoblastic Leukemia. Cancer Research Communications. 3(7). 1248–1259. 4 indexed citations

Rafiq, Sarwish, et al.. (2022). Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma. Cancer treatment and research. 183. 161–184. 7 indexed citations

Hackett, Christopher S., et al.. (2022). Multipurposing CARs: Same engine, different vehicles. Molecular Therapy. 30(4). 1381–1395. 15 indexed citations

Wijewarnasuriya, Dinali, et al.. (2020). Excessive Costimulation Leads to Dysfunction of Adoptively Transferred T Cells. Cancer Immunology Research. 8(6). 732–742. 24 indexed citations

Drakes, Dylan J., Sarwish Rafiq, Terence J. Purdon, et al.. (2020). Optimization of T-cell Receptor–Modified T Cells for Cancer Therapy. Cancer Immunology Research. 8(6). 743–755. 24 indexed citations

Song, Mei, Oladapo Yeku, Sarwish Rafiq, et al.. (2020). Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages. Nature Communications. 11(1). 6298–6298. 111 indexed citations

10.

Yeku, Oladapo, Sarwish Rafiq, Mythili Koneru, et al.. (2020). Abstract IA21: MUC16-directed immunotherapy for ovarian cancer. Clinical Cancer Research. 26(13_Supplement). IA21–IA21. 2 indexed citations

11.

Rafiq, Sarwish, Oladapo Yeku, Terence J. Purdon, et al.. (2018). Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nature Biotechnology. 36(9). 847–856. 628 indexed citations breakdown →

12.

Jin, Chunhui, Jinxing Xia, Sarwish Rafiq, et al.. (2018). Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia. EBioMedicine. 39. 173–181. 49 indexed citations

13.

Rafiq, Sarwish, Oladapo Yeku, Terence J. Purdon, et al.. (2017). Enhancing CAR T Cell Anti-Tumor Efficacy through Secreted Single Chain Variable Fragment (scFv) Immune Checkpoint Blockade. Blood. 130(Suppl_1). 842–842. 6 indexed citations

14.

Rafiq, Sarwish, Terence J. Purdon, Anthony F. Daniyan, et al.. (2016). Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen. Leukemia. 31(8). 1788–1797. 128 indexed citations

15.

Cheney, Carolyn, Deborah M. Stephens, Xiaokui Mo, et al.. (2014). Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia. mAbs. 6(3). 748–754. 35 indexed citations

16.

Rafiq, Sarwish, Jonathan P. Butchar, Carolyn Cheney, et al.. (2013). Comparative Assessment of Clinically Utilized CD20-Directed Antibodies in Chronic Lymphocytic Leukemia Cells Reveals Divergent NK Cell, Monocyte, and Macrophage Properties. The Journal of Immunology. 190(6). 2702–2711. 75 indexed citations

17.

Rafiq, Sarwish, Carolyn Cheney, Gerard Lozanski, et al.. (2010). GlycoVariant Anti-CD37 Small Modular Immuno-Pharmaceutical Exhibits Superior Natural Killer Cell Mediated Cytotoxicity Against Chronic Lymphocytic Leukemia Cells at Low Concentrations and Low Antigen Density. Blood. 116(21). 1847–1847.

18.

Raffaniello, Robert D., et al.. (2009). Hsp90 Co-localizes with Rab-GDI-1 and Regulates Agonist-induced Amylase Release in AR42J Cells. Cellular Physiology and Biochemistry. 24(5-6). 369–378. 15 indexed citations

19.

Baum, Peter, Brian Gordon, C. Nilsson, et al.. (2009). Evaluation of the effect of TRU-016, an anti-CD37 directed SMIP in combination with other therapeutic drugs in models of non-Hodgkin's lymphoma. Journal of Clinical Oncology. 27(15_suppl). 8571–8571. 18 indexed citations

20.

Montero, Estrella, Sarwish Rafiq, Susanne Heck, & Cheryl A. Lobo. (2007). Inhibition of human erythrocyte invasion by Babesia divergens using serine protease inhibitors. Molecular and Biochemical Parasitology. 153(1). 80–84. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact